Branded Legacy, Inc. to Acquire Bio-Legacy Evaluative Group, Expanding into Intranasal Drug Delivery Market

Branded Legacy, Inc. (OTC: BLEG), a company focused on health and wellness solutions, has taken a significant step towards expanding its portfolio by signing a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group. This acquisition, valued at $1.5 million in Preferred D stock, is set to transfer all of Bio-Legacy's equity, assets, and intellectual property to Branded Legacy. The move is aimed at entering the rapidly growing markets for addiction treatments and vaccine accessibility, leveraging Bio-Legacy's patented naloxone device. This device is designed to address the challenges of cost and dosing in a market expected to surpass $1.16 billion by 2032.

Following the completion of this acquisition, Amin Janmohamed, the current CEO of Bio-Legacy, will take on the roles of CEO and Chairman at Branded Legacy. The company has outlined its plans to begin manufacturing prototyping by the third quarter of 2025, with the goal of making the naloxone device market-ready by the first quarter of 2027. This strategic acquisition not only broadens Branded Legacy's product offerings but also positions the company as a key player in the intranasal drug delivery technology space.